Represented Paragon Biosciences Emalex Capital, Inc., a company sponsored by Paragon Biosciences, Inc., in its equity sale to Teva Pharmaceutical Industries, Ltd. Subject to regulatory approval, Emalex’s lead asset, ecopipam — a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome — is expected to strengthen Teva’s late-stage innovative pipeline in neuroscience.